Human immune responses to live attenuated varicella vaccine.
Experiences with the use of the live attenuated varicella vaccine for the immunization of varicella-susceptible adults and healthy and leukemic children are described. Healthy children, for whom a greater than 90% rate of seroconversion and protective efficacy was noted, showed the best response. Leukemic children experienced a 40%-50% rate of vaccine-associated rash; protective efficacy approached 90%. For adults, a 10% rate of vaccine-associated rash and a protective efficacy of 70% were noted. Breakthrough cases of vaccine were mild, indicating modification of the course of the illness by the vaccine.
Gershon
A A
AA
Department of Pediatrics, Columbia University, College of Physicians and Surgeons, New York, New York 10032.
D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis*; D002644:Chickenpox / Q000517:prevention & control*; D019433:Chickenpox Vaccine; D002648:Child; D014645:Herpesvirus 3, Human / Q000276:immunology*; D006801:Humans; D007938:Leukemia / Q000276:immunology*; D014611:Vaccination / Q000009:adverse effects; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology; D014765:Viral Vaccines / Q000009:adverse effects / Q000276:immunology*
D000914:Antibodies, Viral; D019433:Chickenpox Vaccine; D014613:Vaccines, Attenuated; D014765:Viral Vaccines